Insights - XenoPort (XNPT) provided an update to investors in mid-January that shed light on possible approval pathways for clinical stage assets while also commenting on progress … Continue Reading
Read nowInsights - Two weeks ago with the release of data from an ongoing phase 2 study of the company’s oncology candidate, PSMA ADC, shares of Progenics Pharmaceuticals (PGNX) took … Continue Reading
PremiumRecap - Incyte (INCY) has been one of PropThink’s most profitable recommendations in the last year. The stock is up nearly 190% since we first began covering the name in July of 2013. This … Continue Reading
Read nowRecap - It looked briefly at mid-week like the biotech sector’s correction might be a comical 48-hour event, but investors are in a tizzy over the emerging … Continue Reading
Read nowRecap - The congrats this week went to PropThink contributor Ivan Deryugin for his early December suggestion to buy BDSI ahead of a crucial phase 3 readout. The position … Continue Reading
Read nowResearch - With the JP Morgan Healthcare conference in the rearview, here are updates on a few names that PropThink suggested already this year, all of which … Continue Reading
PremiumInsights - Our entire editorial team was in San Francisco this week for the annual confluence of biotech conferences – JP Morgan Healthcare, Biotech Showcase, and OneMedForum … Continue Reading
Read now
